SeraCare Bioservices is Now Precision Bioservices, Inc.

I am very excited to announce that the SeraCare Bioservices repository will now be Precision Bioservices, Inc, a wholly owned subsidiary of Precision Health Holdings. Precision Health is committed to the advancement of Personalized Medicine by supporting the life sciences community to accelerate development and commercialization of individualized medicines and targeted therapeutics.

Precision Health shares the same values we do and exceeded our hopes for a company we can combine with. Together, we are committed to continue the tradition for excellent service, deep expertise, and an environment our clients and associates want to be a part of.

Kathi Shea
Vice President, Bioservices Operations
Precision Bioservices, Inc

Andy Zaayenga Uses Creative Technology to Survive During Superstorm Sandy

Our resident ISBER Technocrat, Andy Zaayenga, used his faithful Prius hybrid automobile to help his family survive during the Hurricane Sandy, the Superstorm that ravaged the New York City and New Jersey coastal area. Andy’s Facebook page chronicled their struggle: “Sweet Prius, powering the house through day 9 of no power and a nor’easter at under 7 ounces of gas per hour...” It powered their refrigerator, computer TV, FIOS, phone, network, and some lights, using at peak only 400 out of 1000 potential watts, thus letting Andy save the portable generator for more critical uses such as water refills and showers – important when few gas stations were open and purchase lines were four hours long.

Andy also directed readers interested in this process to an excellent NBC News how-to article with valuable safety information: http://editorial.autos.msn.com/blogs/autosblogpost.aspx?post=7f887013-60d3-4465-a14b-6bbf588c03bc (“How a Prius can power your home in an outage - At least two resourceful hybrid owners were able to watch TV while their neighbors were stranded in the dark during the blackouts after Sandy.”)

For another commentary on how the research community was affected, see: “NYC Science Stunned by Sandy” (http://www.the-scientist.com/?articles/view/articleNo/33109/title/NYC-Science-Stunned-by-Sandy/) and “Sandy vs. Science: On Long Island, Prominent Research Lab Weathers the Storm” (http://news.sciencemag.org/scienceinsider/2012/11/sandy-vs-science-on-long-island-.html).

UF CTSI Biorepository Achieves Accreditation From College of American Pathologists

On November 1, 2012, the University of Florida Clinical and Translational Science Institute (CTSI) Biorepository (http://biorepository.pathology.ufl.edu/) became the 12th biorepository to achieve College of American Pathologists (CAP) accreditation based on results of a recent on-site inspection. The facility’s director, Michael J. Clare-Salzler, MD, was advised of this national recognition by CAP President, Stanley J. Robboy, MD, FCAP, and was congratulated for the excellence of the services being provided.

The UF CTSI Biorepository was conceived in mid-2009 and has undergone a tremendous evolution over the last couple of years in order to fulfill the mission of providing extensive biobanking infrastructure to support translational research conducted by investigators at UF and beyond. It provides a variety of services, including the creation of an institutional biospecimen library as well as tissue procurement and storage for investigator-led studies, such as a national aging trial involving 10 sites across the U.S. for which the biorepository manages 252,000 aliquots. The goal of the UF CTSI Biorepository is to ensure the highest quality biospecimens through adherence to strict operating procedures, redundant and automated storage, inventory tracking, and emergency response planning. It is also closely integrated with other institutional resources, including the UF academic health center’s integrated data repository and a system-wide consent process through which patients can allow the UF CTSI Biorepository to store biospecimens leftover from their healthcare visits for future use in research.

The Biorepository houses equipment for storage, processing and sample tracking, and equipment temperature monitoring. Samples are stored in automated sample management systems (2) or manual freezers (8) at -80°C with either CO2 or LN2 back-up, emergency power back-up, and a 24/7/365 remote monitoring system. Liquid nitrogen storage will be developed to expand the infrastructure and cell storage...
Promoting consistent, high quality standards, ethical principles and innovation in biospecimen banking throughout the global biobanking community.

Smart Moves
(Continued from page 14)

The capabilities of the Biorepository, which also has equipment for both small volume DNA, RNA and protein purification and for quality-control analysis. The samples stored within the Biorepository are securely managed using a web-based Laboratory Information Management System (LIMS), and information regarding availability of samples is accessible through the university’s integrated data repository. The LIMS software supports all aspects of biospecimen management including tracking of patient consent, collection and annotation of biospecimens, storage location and quantity, capture of quality assurance data, and distribution of samples to ensure proper chain of custody. The database management system also allows comprehensive searches and has reporting features that provide flexible biospecimen reporting capabilities. The Standard Operating Procedures used by the Biorepository are managed using an electronic data management system and are based on the best-practice guidelines set forth by ISBER and the NCI Biorepositories and Biospecimen Research Branch (BBRB).

The desire to provide the highest quality biospecimens led the UF CTSI Biorepository staff to seek accreditation by the College of American Pathologists. The CAP Biorepository Accreditation Program is based on the principles of its Laboratory Accreditation Program. It is a three-year accreditation cycle, including an on-site inspection, desk review, and optional education modules and gap assessment. As part of the on-site inspection, the CAP uses Accreditation Checklists to provide a comprehensive and up-to-date blueprint of quality practices to assist biorepositories in improving their operations and ensure quality. Further, a desk review offers a remote review of a biorepository’s quality management plan, certain procedures and select quality and process statistics. The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program. Currently, there is no federal mandate for biorepository accreditation.

ISBER has been working closely with CAP on this program. At the May 2012 meeting in Vancouver, ISBER members were invited to be trained as inspectors for this program and do the following:

- Lead a CAP inspection team,
- Discover, synthesize, and assess processes to a requirement, and
- Understand the philosophy of CAP inspections and deliver the value of CAP Accreditation to the biorepository industry.

Mark Cosentino - Director of Biogen Biobank
Long-time ISBER member (Louis) Mark Cosentino has accepted a position with Biogen Idec, the oldest independent biotechnology company in the world, making products for the treatment of multiple sclerosis and new therapies for patients with neurodegenerative diseases, autoimmune disorders and hemophilia. Mark will serve as Director of the Biobank for Translational Medicine at the Biogen Idec facility in Cambridge, MA. Previously Mark was Project Manager for the Central Repository, Head of the Bioprocessing Laboratory, & Head of the DNA Extraction Laboratory at the SAIC Biorepository facility in Frederick, MD, working on many biorepository projects for NCI.

Brett Roberts Promoted to the Position of Commercial Director for Bluechip, Ltd, of Australia
Bluechip (an ISBER Platinum Corporate Partner) offers a proprietary Radio Frequency Identification (RFID) system, including chips and an interrogator system that will provide customers with key functional advantages that cannot be met by alternative RFID technologies. At Bluechip, Brett is responsible for planning, controlling and managing sales, marketing and business development activities. He is an experienced senior leader with a track record of delivering results in complex and challenging environments across a broad range of industries. (Read more at http://www.bluechip.com/about-us/team/brett-roberts/)

ISBER Corporate Partnerships
Highlighting your products and services to the international specimen repository community!

Corporate Partnerships are designed to provide ISBER member organizations additional high-visibility opportunities to highlight their company, products and services at the Annual Meeting and on the ISBER website.

Partnerships provide unparalleled opportunities to connect with professionals in the specimen collection and storage industry in domestic and international markets.

www.isber.org/CP

Promoting consistent, high quality standards, ethical principles and innovation in biospecimen banking throughout the global biobanking community.